Yu LF, Zhang ZM, Yuan CJ, Chen FM, Peng YY. Clinical effect of PEG-IFN in treatment of CHC and HCV/HBV co-infection.
Shijie Huaren Xiaohua Zazhi 2013;
21:3270-3274. [DOI:
10.11569/wcjd.v21.i30.3270]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To observe the clinical effect of pegylated interferon (PEG-IFN) in the treatment of chronic hepatitis C (CHC) and hepatitis C virus/hepatitis B virus (HCV/HBV) co-infection.
METHODS: Venous samples were collected from 25 CHC patients and 25 HCV/HBV patients for detection of HCV RNA, HBV DNA and liver fibrosis.
RESULTS: After one year of treatment, the rate of HCV RNA negativity was 52.0% in the CHC group and 28.0% in the HCV/HBV group (P < 0.05); liver function was improved in both groups (both P < 0.05), and the improvement did not differ significantly between the two groups (P > 0.05); and posttreatment hyaluronic acid level was significantly lower than pretreatment value in the HCV group (P < 0.05).
CONCLUSION: Although PEG-IFN has a better clinical effect in the treatment of CHC than HCV/HBV co-infection, it has an inhibitory effect on HCV and can partly improve the body's immune function and liver function.
Collapse